» Articles » PMID: 34865544

The Inefficient and Unjust Global Distribution of COVID-19 Vaccines: From a Perspective of Critical Global Justice

Overview
Journal Inquiry
Date 2021 Dec 6
PMID 34865544
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The coronavirus disease 2019 (COVID-19) pandemic has caused huge losses and massive damage to socio-economic development around the globe, which might even potentially evolve into a humanitarian crisis as it continues to spread. In response to the further resulting public threats, collaborative research, rapid production, and efficient and just distribution of vaccines have been given a top priority. However, there exists a serious inefficiency and injustice in the distribution of COVID-19 vaccines among different countries, regions, and social classes currently. Richer countries and regions have acquired far more vaccines than needed, further exacerbating the severity of the epidemic in underdeveloped and marginalized countries and regions. From a perspective of critical global justice, we explore the causes of the inefficient and unjust global distribution of vaccines and comprehensively examine the shortcomings of the current distribution frameworks, such as COVID-19 Vaccines Global Access Facility (COVAX). Then, under the framework of critical global justice, we propose a multi-phase fair priority model that improves the existing proportional distribution mechanism. This solution to the global injustice reoptimizes the cross-border and domestic vaccine distribution and aims to resolve the pandemic more efficiently. The proposed framework and methodology of vaccine distribution could be taken as an opportunity to consistently promote the development of the global socio-economic structure towards global justice more broadly and systematically.

Citing Articles

COVID-19 ethics: unique aspects and a review as of early 2024.

Shandera W Monash Bioeth Rev. 2024; 42(1):55-86.

PMID: 39003388 PMC: 11368997. DOI: 10.1007/s40592-024-00199-x.


New Trends in Vaccine Characterization, Formulations, and Development.

Kumar R Vaccines (Basel). 2024; 12(3).

PMID: 38543972 PMC: 10974585. DOI: 10.3390/vaccines12030338.


A critical analysis of COVAX alliance and corresponding global health governance and policy issues: a scoping review.

Pushkaran A, Chattu V, Narayanan P BMJ Glob Health. 2023; 8(10).

PMID: 37793808 PMC: 10551961. DOI: 10.1136/bmjgh-2023-012168.


Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries.

Mukherjee S, Kalra K, Phelan A PLOS Glob Public Health. 2023; 3(6):e0002098.

PMID: 37384623 PMC: 10309624. DOI: 10.1371/journal.pgph.0002098.


Determinants of COVID-19 immunisation uptake in a country with high mortality and a low vaccination rate.

Aksentijevic D, Tanner R, Lazovic-Pita L, Pestek A, Abdic A J Infect Public Health. 2023; 16(8):1322-1331.

PMID: 37343504 PMC: 10239289. DOI: 10.1016/j.jiph.2023.06.001.


References
1.
Usher A . South Africa and India push for COVID-19 patents ban. Lancet. 2020; 396(10265):1790-1791. PMC: 7831528. DOI: 10.1016/S0140-6736(20)32581-2. View

2.
Fidler D . Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1. PLoS Med. 2010; 7(5):e1000247. PMC: 2864298. DOI: 10.1371/journal.pmed.1000247. View

3.
Emanuel E, Luna F, Schaefer G, Tan K, Wolff J . Enhancing the WHO's Proposed Framework for Distributing COVID-19 Vaccines Among Countries. Am J Public Health. 2021; 111(3):371-373. PMC: 7893355. DOI: 10.2105/AJPH.2020.306098. View

4.
Saksena N . Global justice and the COVID-19 vaccine: Limitations of the public goods framework. Glob Public Health. 2021; 16(8-9):1512-1521. DOI: 10.1080/17441692.2021.1906926. View

5.
Schmidt H, Gostin L, Williams M . Is It Lawful and Ethical to Prioritize Racial Minorities for COVID-19 Vaccines?. JAMA. 2020; 324(20):2023-2024. DOI: 10.1001/jama.2020.20571. View